Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2

Conclusions: Albumin fusion deflects KPI from rapidin vivo clearance without impairing its antithrombotic properties and widens its potential therapeutic window.Cell Physiol Biochem 2018;45:772 –782
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research